Treatment of acute (adult) respiratory distress syndrome. The holy grail of surfactant therapy

Biology of the Neonate

Volumn 77, Issue SUPPL. 1, 2000, Pages 2-8

  Taeusch, H William ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Center for Vulnerable Populations   (United States)

Author keywords

Acute respiratory distress syndrome; Dextrans; Meconium aspiration; Polyethylene glycols; Pulmonary surfactants; Surfactant proteins

Indexed keywords

ARTIFICIAL LUNG SURFACTANT; LUNG SURFACTANT; LUNG SURFACTANT EXTRACT;

ADULT RESPIRATORY DISTRESS SYNDROME; CONFERENCE PAPER; HUMAN; LUNG INJURY; NEONATAL RESPIRATORY DISTRESS SYNDROME; PRIORITY JOURNAL;

EID: 0034024430     PISSN: 00063126     EISSN: None     Source Type: Journal    
DOI: 10.1159/000047050     Document Type: Conference Paper

References (81)

1. Avery ME, Mead J: Surface properties in relation to atelectasis and hyaline membrane disease. Am J Dis Child 1959;97:517-523.
2. Tierney D, Johnson R: Altered surface tension of lung extracts and lung mechanics. J Appl Physiol 1965;20:1253-1260.
3. Staub N, Nagano H, Pearce M: Pulmonary edema in dogs, especially the sequence for fluid accumulation in lungs. J Appl Physiol 1967;22: 227-240.
4. Wyszogrodski I, Kyei-Aboagye K, Taeusch HW, Avery ME: Inactivation of surfactant by hyperventilation: conservation of end-expiratory pressure. J Appl Physiol 1975:38:461-466.
5. Enhorning G, Shumel B, Keicher L, Sokoloski J, Holm B: Phospholipases introduced into the hypophase affect the surfactant film outlining a bubble. J Appl Physiol 1992;73:941-945.
6. 2 protein interaction. J Clin Invest 1998;102:1152-1160.
7. Obata M, Ohama Y, Kakinuma R, Kawasaki H, Shimizu H, Ogawa Y: Pulmonary surfactant subtypes in a newborn piglet model of meconum aspiration syndrome. Am J Respir Crit Care Med 1998;157:A444.
8. Hall S, Hyde R, Kahn M: Stabilization of lung surfactant particles against conversion by a cycling interface. Am J Physiol 1997;272:L335-L343.
9. Günther A, Schmidt R, Feustel A, Meier U, Pucker C, Ermert M, Seeger W: Surfactant subtype conversion is related to loss of surfactant apoprotein B and surface activity in large surfactant aggregates. Experimental and clinical studies. Am J Respir Crit Care Med 1999;159: 244-251.
10. Putman E, Boere A, Van Bree L, Haagsman H: Pulmonary surfactant subtype metabolism is altered after short-term ozone exposure. Toxicol Appl Pharmacol 1995;134:132-138.
11. Reed J, Ikegami M, Cianciolo E, Lu W, Cho P, Hull W, Jobe A, Whitsett J: Aerosolized GM-CSF ameliorates pulmonary alveolar proteinosis in GM-CSF-deficient mice. Am J Physiol 1999;276:L556-L563.
12. Ueda T, Ikegami M, Jobe A: Surfactant subtypes: In vitro conversion, in vivo function, and effects of serum proteins. Am J Respir Crit Care Med 1994;149:1254-1259.
13. Hall S, Hyde R, Kahn M: Stabilization of lung surfactant particles against conversion by a cycling interface. Am J Physiol 1997;272:L335-L343.
14. Magoon M, Wright J, Baritussio A, Williams M, Goerke J, Benson B, Hamilton R, Clements J: Subfractionation of lung surfactant. Implications for metabolism and surface activity. Biochim Biophys Acta 1983;750:18-31.
15. Gross NJ, Schultz RM: Serine proteinase requirement for the extra-cellular metabolism of pulmonary surfactant. Biochim Biophys Acta 1990;1044:222-230.
16. Bac C, Takahashi A, Chida S, Sasaki M: Morphology and function of pulmonary surfactant inhibited by meconium. Pediatr Res 1998;44: 187-191.
17. Veldhuizen R, Yao L, Hearn S, Possmayer F, Lewis J: Surfactant-associated protein A is important for maintaining surfactant large-aggregate forms during surface-area cycling. Biochem J 1996;313:835-840.
18. Hall S, Lu R, Venkitaraman A, Hyde R, Notter R: Inhibition of pulmonary surfactant by oleic acid: Mechanisms and characteristics. J Appl Physiol 1992;72:1708-1716.
19. Clark D, Nieman G, Thompson J, Paskanik A, Rokhar J, Bredenberg C: Surfactant displacement by meconium free fatty acids: An alternative explanation for atelectasis in meconium aspiration syndrome. J Pediatr 1987;110:765-770.
20. Cockshutt A, Possmayer F: Lysophosphatidylcholine sensitizes lipid extracts of pulmonary surfactant to inhibition by serum proteins. Biochim Biophys Acta 1991;1086:63-71.
21. Davies R, Genghini M, Walters D, Morley C: The behaviour of lung surfactant in electrolyte solutions. Biochim Biophys Acta 1986;878: 135-145.
22. Amirkhanian JD, Taeusch HW: Reversible and irreversible inactivation of preformed pulmonary surfactant surface films by changes in subphase constituents. Biochim Biophys Acta 1993;1165:321-326.
23. Holm B, Enhorning G, Notter R: A biophysical mechanism by which plasma proteins inhibit lung surfactant activity. Chem Phys Lipids 1988;49:49-55.
24. McEachern T, Keough K: Phosphocholine reverses inhibition of pulmonary surfactant caused by C-reactive protein. Am J Physiol 1995;265:L492-L497.
25. Seeger W, Stöhr G, Wolf H, Neuhof H: Alteration of surfactant function due to protein leakage: Special interaction with fibrin monomer. J Appl Physiol 1985;58:326-338.
26. Walters R, Jenq R, Hall SB: Distinct steps in the adsorption of pulmonary surfactant to an air-liquid interface. Biophys J 2000;78:257-266.
27. Wang Z, Notter RH: Additivity of protein and nonprotein inhibitors of lung surfactant activity. Am J Respir Crit Care Med 1998;158:28-35.
28. Robertson B, van Golde L, Batenburg J (eds): Pulmonary Surfactant: From Molecular Biology to Clinical Practice. Amsterdam, Elsevier, 1992.
29. Batenburg J, Haagsman H: The lipids of pulmonary surfactant: dynamics and interactions with proteins. Progr Lipid Res 1998;37:235-276.
30. Goerke J: Pulmonary surfactant: Functions and molecular composition. Biochim Biophys Acta 1998;1408:79-89.
31. Robertson B, Kobayashi T, Ganzuka M, Grossmann G, Wen-zhi L, Suzuki Y: Experimental neonatal respiratory failure induced by a monoclonal antibody to the hydrophobic surfactant-associated protein, SP-B. Pediatr Res 1991;30:239-243.
32. Haagsman H: Toxicological aspects of the surfactant system; in Robertson B, van Golde L, Batenburg J (eds): Pulmonary Surfactant: From Molecular Biology to Clincial Practice. Amsterdam, Elsevier, 1992, pp 705-734.
33. Hall S, Venkitaraman A, Whitsett J, Holm B, Notter R: Importance of hydrophobic apoproteins as constituents of clincal exogenous surfactants. Am Rev Respir Dis 1992;145:24-30.
34. Seeger W, Grube C, Gunther A, Schmidt R: Surfactant inhibition by plasma proteins: differential sensitivity of various surfactant preparations. Eur Respir J 1993;6:971-977.
35. Mbagwu N, Bruni R, Hernandez-Juviel J, Waring A, Walther F: Sensitivity of synthetic surfactants to albumin inhibition in preterm rabbits. Mol Genet Metab 1999;66:40-48.
36. 4. Pediatr Res 1996;39:947-952.
37. Häfner D, Germann P-G, Hauschke D: Effects of rSP-C surfactant on oxygenation and histology in a rat lung lavage model of acute lung injury. Am J Respir Crit Care Med 1998;158: 270-278.
38. Amirkhanian JD, Bruni R, Waring AJ, Taeusch HW: Inhibition of mixtures of surfactant lipids and synthetic sequences of surfactant proteins SP-B and SP-C. Biochim Biophys Acta 1991;1096:355-360.
39. Rider E, Ikegami J, Whitsett J, Hull W, Absolom D, Jobe A: Treatment responses to surfactants containing natural surfactant proteins in preterm rabbits. Am Rev Respir Dis 1993;147: 669-676.
40. Mizuno K, Ikegami M, Chen C, Ueda T, Jobe A: Surfactant protein B supplementation improves in vivo function of a modified natural surfactant. Pediatr Res 1995;37:271-276.
41. Häfner D, Beume R, Kilian U, Krasznai G, Lachmann B: Dose response comparisons of five lung surfactant preparations in an animal model of ARDS. Br J Pharmacol 1995;115: 451-458.
42. Ueda T, Ikegami M: Change in properties of exogenous surfactant in injured rabbit lung. Am J Respir Crit Care Med 1996;153:1844-1849.
43. Lewis J, McCaig L, Häfner D, Spragg R, Veldhuizen R, Kerr C: Dosing and delivery of a recombinant surfactant in lung-injured adult sheep. Am J Respir Crit Care Med 1999;159: 741-747.
44. Tokieda K, Ikegami M, Wert SE, Baatz JE, Zou Y, Whitsett JA: Surfactant protein B corrects oxygen-induced pulmonary dysfunction in heterozygous surfactant protein B-deficient mice. Pediatr Res 1999;46:708-714.
45. Cockshutt A, Weitz J, Possmayer F: Pulmonary surfactant-associated protein A enhances the surface activity of lipid extract surfactant and reverses inhibition by blood proteins in vitro. Biochemistry 1990;29:8424-8429.
46. Yukitake K, Brown C, Schluetcr M, Clements J, Hawgood S: Surfactant apoprotein A modifies the inhibitory effect of plasma proteins on surfactant activity in vivo. Pediatr Res 1995; 37:21-25.
47. Strayer D, Herting E, Sun B, Robertson B: Antibody to surfactant protein A increases sensitivity of pulmonary surfactant to inactivation by fibrinogen in vivo. Am J Respir Crit Care Med 1996;153:1116-1122.
48. Sun B, Curstedt T, Lindgren G, Franzén B, Alaiya A, Calkovská A, Robertson B: Biophysical and physiological properties of a modified porcine surfactant enriched with surfactant protein A. Eur Respir J 1997;10:1967-1974.
49. Ikegami M, Korfhagen T, Whitsett J, Bruno M, Wert S, Wada K, Jobe A: Characteristics of surfactant from SP-A-deficient mice. Am J Physiol 1998;275:L247-L254.
50. Elhalwagi B, Zhang M, Ikegami M, Iwamoto H, Morris R, Miller M, Dienger K, McCormack F: Normal surfactant pool sizes and inhibition-resistant surfactant from mice that overexpress surfactant protein A. Am J Respir Cell Mol Biol 1999;21:380-387.
51. Günther A, Schmidt R, Feustel A, Meier U, Pucker C, Ermert M, Seeger W: Surfactant subtype conversion is related to loss of surfactant apoprotein B and surface activity in large surfactant aggregates. Am J Respir Crit Care Med 1999;159:244-251.
52. Keough K: Surfactant composition and extracellular transformations; in Rooncy S (ed): Lung Surfactant: Cellular and Molecular Processing. Georgetown, Landes, 1998, pp 1-27.
53. Krüger P, Schalke M, Wang Z, Notter R, Dluhy R, Lösche M: Effect of Hydrophobic surfactant peptides SP-B and SP-C on binary phospholipid monolayers. I. Fluorescence and dark-field microscopy. Biophys J 1999;77:903-914.
54. Schürch S, Qanbar R, Bachofen H, Possmayer F: The surface-associated surfactant reservoir in the alveolar lining. Biol Neonate 1995:67: 61-76.
55. Amrein M, von Nahmen A, Sieber M: A scanning force-and fluorescence light microscopy study of the structure and function of a model pulmonary surfactant. Eur Biophys J 1997;26: 349-357.
56. van Rozendaal B, van de Lest C, van Eijk M, van Golde L, Voorhout W, van Helden H, Haagsman H: Aerosolized endotoxin is immediately bound by pulmonary surfactant protein D in vivo. Biochim Biophys Acta, 1999:1454: 261-269.
57. Lewis J, Jobe A: Surfactant and the adult respiratory distress syndrome. Am Rev Respir Dis 1993;147:218-233.
58. Seeger W, Günther A, Walmrath H. Gimminger F, Lasch H: Alveolar surfactant and ARDS: Pathogenic role and terapcutic prospects. Clin Invest 1993;71:177-190.
59. Griese M: Pulmonary surfactant in health and human lung diseases: State of the art. Eur Respir J 1999;13:1455-1476.
60. Günther A, Siebert C, Schmidt R, Ziegler S, Grimminger F, Yabut M, Temmesfeld B, Walmrath D, Morr H, Seeger W: Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am J Respir Crit Care Med 1996;153: 176-184.
61. Kari M, Raivio K, Venge P, Hallman M: Dexamethasone treatment of infants at risk for chronic lung disease: Surfactant components and inflammatory parameters in airway specimens. Pediatr Res 1994;36:387-393.
62. Hallman M, Merritt T, Akino T, Bry K: Surfactant protein A, phosphatidylcholine, and surfactant inhibitors in epithelial lining fluid: Correlation with surface activity, severity of respiratory distress syndrome, and outcome in small premature infants. Am Rev Respir Dis 1991; 144:1376-1384.
63. Hallman M, Maasilta P, Kivisaari L, Mattson K: Changes in surfactant in bronchoalveolar lavage fluid after hemithorax irradiation in patients with mesothelioma. Am Rev Respir Dis 1990;141:998-1005.
64. 4-surfactant in preterm infants with respiratory distress syndrome. Am J Respir Crit Care Med 1996;153:404-410.
65. Walmrath D, Günther A, Ghofrani H, Schermuly R, Schneider T, Grimminger F, Seeger W: Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis. Am J Respir Crit Care Med 1996;154:57-62.
66. Gregory T, Longmore M, Moxley M, Whitsett J, Reed C, Fowler A, Hudson L. Maunder R, Crim C, Hyers T: Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J Clin Invest 1991;88: 1976-1981.
67. Greene K, Wright J, Steinberg K, Ruzinski J, Caldwell E, Wong W, Hull W, Whitsett J, Akino T, Kuroki Y, Nagae H, Hudson L, Martin T: Serial changes in surfactant-associated proteins in lung and serum before and after the onset of ARDS. Am Rev Respir Crit Care Med 1999; 160:1843-1850.
68. Gregory T, Steinberg K, Spragg R, Gadek J, Hyers T, Longmore W, Moxley M, Cai G, Hite R, Smith R, Hudson L, Crim C, Newton P, Mitchell B, Gold A: Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1997;155: 1309-1315.
69. Anzueto A, Baughman R, Guntupalli K, Weg J, Wiedemann H, Raventós A, Lemaire F, Long W, Zaccardelli D, Pattishall E: Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. N Engl J Med 1996;334:1417-1421.
70. 4 surfactant) for ARDS. Am J Respir Crit Care Med 1999;159:A378.
71. Häfner D, Germann P-G, Hauschke D, Kilian U: Effects of early treatment with rSP-C surfactant on oxygenation and histology in rats with acute lung injury. Pulm Pharmacol Ther 1999; 12:193-201.
72. Leach CL, Greenspan JS, Rubenstein SD, Shaffer TH, Wolfson MR, Jackson JC, De Lemos R, Fuhrman BP: Partial liquid ventilation with perflubron in premature infants with severe respiratory distress syndrome. N Engl J Med 1996;335:761-767.
73. Doctor A, Mazzoni M, BelBalzo U, DiCanzio J, Arnold J: High-frequency oscillatory ventilation of the perfluorocarbon-filled lung: Preliminary results in an animal model of acute lung injury. Crit Care Med 1999;27:2500-2507.
74. Mrozek J, Smith K, Simonlon S, Bing D, Meyers P, Connett J, Mammel M: Perfluorocarbon priming and surfactant: physiologic and pathologic effects. Crit Care Med 1999;27: 1916-1922.
75. Bleyl J, Ragaller M, Tschö U, Regner M, Kanzow M, Hübler M, Rasche S, Albrecht M: Vaporized perfluorocarbon improves oxygenation and pulmonary function in an ovine model of acute respiratory distress syndrome. Anesthesiology 1999;91:461-469.
76. Taeusch H, Lu K, Goerke J, Clements J: Nonionic polymers reverse inactivation of surfactant by meconium and other substances. Am J Respir Crit Care Med 1999;159:1391-1395.
77. Sarin P, Taeusch H, Lu K, Goerke J, Clements J: Polyethylene glycol results in concentration-dependent sedimentation of Survanta and improvement of its function. Pediatr Res 1999; 45:319A.
78. Lu K, Taeusch H, Robertson B, Clements J, Goerke J: Polymer-surfactant treatment of meconium-induced acute lung injury. Am J Respir Crit Care Med, in press.
79. Taeusch H, Keough K: Inactivation of pulmonary surfactant and the treatment of acute lung injuries. Pediatr Pathol Mol Med, in press.
80. Kobayashi T, Ohta K, Tashiro K, Nishizuka K, Chen W, Ohmura S, Yamamoto K: Dextran restores albumin-inhibited surface activity of pulmonary surfactant extract. J Appl Physiol 1999;86:1778-1784.
81. Kuhl T, Guo Y, Aldefer J, Berman A, Leckband D, Israelachvili J, Hui S: Direct measurement of PEG induced depletion attraction between bilayers. Langmuir 1996;12:3003-3014.